Immunodeficiency and HIV/AIDS

An immunodeficiency is any heritable or acquired failure of the immune system to mount an adequate protective response. Immunologists classify these into primary immunodeficiencies (PIDs), caused by inherited mutations in specific immune genes and usually presenting in infancy or childhood, and secondary (acquired) immunodeficiencies, caused by an external factor acting on an otherwise normal immune system — malnutrition, cancer chemotherapy, immunosuppressive drugs used in transplantation, or infection. More than 450 distinct PID gene defects are now catalogued, but they cluster into a small number of functional categories: antibody (B cell) deficiencies, T-cell (cellular) deficiencies, combined B/T deficiencies, phagocyte defects, and complement deficiencies. Each category produces a recognizable infection signature because each arm of immunity specializes in controlling a different class of pathogen — a direct consequence of the division of labor established during T-Cell Activation and lymphocyte differentiation. HIV (human immunodeficiency virus) causes the single most important acquired immunodeficiency in human history, having infected roughly 85 million people since the epidemic began and causing an estimated 40 million deaths. HIV is unusual among secondary immunodeficiencies because it does not merely suppress immunity nonspecifically (as chemotherapy or malnutrition do); it selectively targets and destroys CD4-expressing helper T cells, the cells that license both antibody responses and cytotoxic T-cell responses. The clinical syndrome that results from this depletion — the point at which the immune system can no longer control opportunistic organisms — is called AIDS (acquired immunodeficiency syndrome), formally defined by a CD4 count below 200 cells/µL (normal is roughly 500–1500 cells/µL) or the occurrence of any of a defined list of AIDS-defining illnesses, regardless of CD4 count. The conceptual payoff of studying HIV is that it isolates the CD4 T-cell variable with a precision no genetic knockout could easily match in humans: the virus itself performs the "experiment," destroying one cell population over years while investigators track exactly which infections emerge at exactly which CD4 thresholds. This has made HIV pathogenesis a master class in mapping immune cell function onto clinical vulnerability.

Primary immunodeficiency logic. Consider the functional map first, because HIV's damage is best understood against it. Antibody deficiencies (e.g., X-linked agammaglobulinemia, caused by mutations in the BTK gene that block B-cell maturation) leave patients susceptible to recurrent infections with encapsulated extracellular bacteria — Streptococcus pneumoniae, Haemophilus influenzae — because opsonizing antibody is needed to tag these organisms for phagocytosis. T-cell deficiencies (e.g., DiGeorge syndrome, thymic hypoplasia from a 22q11.2 deletion) leave patients susceptible to viruses, intracellular bacteria, and fungi, because cellular immunity — cytotoxic killing and macrophage activation — handles those. Combined severe combined immunodeficiency (SCID, e.g., defects in the common gamma chain shared by many cytokine receptors, or in RAG1/RAG2 recombinase genes needed for antigen receptor gene rearrangement) wipes out both arms and is fatal in infancy without a bone marrow transplant. Phagocyte defects (e.g., chronic granulomatous disease, a defect in the NADPH oxidase complex that generates the microbicidal respiratory burst) predispose to catalase-positive bacterial and fungal infections. Complement deficiencies (e.g., terminal complement component C5–C9 defects) predispose specifically to Neisseria infections, because the membrane attack complex is the primary defense against these organisms.

HIV entry and the viral life cycle. HIV is a lentivirus in the Retroviridae family, carrying two copies of positive-sense single-stranded RNA genome inside a capsid, surrounded by an envelope studded with gp120/gp41 spike proteins. Entry proceeds in defined steps: 1. Attachment. The envelope glycoprotein gp120 binds CD4 on the T-cell surface with high affinity, inducing a conformational change. 2. Coreceptor binding. The altered gp120 exposes a site that binds a chemokine coreceptor — CCR5 (used by macrophage-tropic, transmitted "R5" strains) or CXCR4 (used by T-cell–tropic "X4" strains that tend to emerge later in infection). 3. Fusion. Coreceptor binding triggers gp41 to insert its fusion peptide into the host membrane, pulling viral and cellular membranes together and releasing the capsid into the cytoplasm. 4. Reverse transcription. The viral enzyme reverse transcriptase copies the RNA genome into double-stranded DNA. This enzyme lacks proofreading (no 3′→5′ exonuclease activity), so it makes roughly one error per genome per replication cycle — the molecular basis of HIV's extraordinary mutation rate and its ability to escape immune recognition and generate drug resistance. 5. Integration. Viral integrase inserts this DNA into the host chromosome, creating a provirus — the step that establishes lifelong latency potential, because an integrated, transcriptionally silent provirus is invisible to both antibody and cytotoxic T cells. 6. Transcription and assembly. In activated cells, host RNA polymerase II transcribes the provirus; viral protease cleaves precursor polyproteins to generate mature structural proteins; new virions bud from the plasma membrane.

How CD4 T cells actually die. This is the mechanistic heart of AIDS pathogenesis, and it involves three distinct, synergistic killing mechanisms, clarified largely through work in the 2000s and 2010s:

• Direct cytopathic effect. Productively infected CD4 T cells die from the sheer metabolic burden of viral replication, budding-induced membrane damage, and accumulation of unintegrated viral DNA that triggers a DNA-damage response.
• CD8 cytotoxic T-lymphocyte (CTL) killing. CD8 T cells recognize HIV peptides presented on MHC class I and kill infected CD4 T cells by perforin/granzyme-mediated apoptosis — an essential control mechanism, but one that consumes infected cells rather than sparing them.
• Pyroptosis of abortively infected bystander cells. This is the dominant mechanism of CD4 loss in lymphoid tissue, established by Greene and colleagues (2010s): the great majority of CD4 T cells in lymph nodes and gut-associated lymphoid tissue are resting cells that HIV cannot productively infect (reverse transcription stalls due to low nucleotide pools and restriction factors like SAMHD1). These cells accumulate incomplete cytosolic viral DNA, which is sensed by the innate DNA sensor IFI16, activating caspase-1 and the inflammasome, triggering pyroptosis — a highly inflammatory form of cell death that releases IL-1β and recruits more CD4 T cells to become infected, in a self-amplifying cycle. This explains why roughly 95% of CD4 T-cell death in lymphoid tissue occurs in cells that were never productively infected.

Compounding all three mechanisms is destruction of the thymus and lymphoid architecture (fibrosis of lymph node germinal centers reduces the pool available for T-cell homeostatic replenishment) and massive early depletion of gut-associated lymphoid tissue (GALT), which harbors the majority of the body's CCR5+ memory CD4 T cells and is devastated within the first weeks of infection — well before blood CD4 counts show much change, and a key reason gut barrier damage and microbial translocation drive chronic immune activation throughout the disease course.

The causal chain — HIV infects CD4 T cells → CD4 T cells decline → immunodeficiency → opportunistic disease — was established through a convergence of clinical observation, virus isolation, and molecular/immunological experiments, not a single decisive study.

Clinical recognition (1981). The CDC's Morbidity and Mortality Weekly Report documented clusters of Pneumocystis carinii pneumonia (now P. jirovecii) in previously healthy young men in Los Angeles, and Kaposi sarcoma clusters in New York — diseases normally seen only in severely immunosuppressed patients. Michael Gottlieb and colleagues noted profoundly low helper (CD4) T-cell counts in these patients relative to suppressor (CD8) T cells, an inverted CD4:CD8 ratio that became an early diagnostic clue that a specific lymphocyte subset was being lost.

Viral isolation (1983–1984). Françoise Barré-Sinoussi and Luc Montagnier at the Institut Pasteur isolated a retrovirus from the lymph node of a patient with lymphadenopathy, detecting reverse transcriptase activity in culture supernatants — the enzymatic signature of a retrovirus — and named it lymphadenopathy-associated virus (LAV). Robert Gallo's group at the NCI independently isolated a similar virus (HTLV-III) and, critically, developed a blood test for antibodies against it, enabling large-scale epidemiological confirmation that this virus tracked with AIDS cases. The viruses were shown to be the same agent and renamed HIV in 1986. Barré-Sinoussi and Montagnier received the Nobel Prize in Physiology or Medicine in 2008 for this discovery.

Proving CD4 is the receptor. David Klatzmann and colleagues (1984) showed that anti-CD4 monoclonal antibodies blocked HIV infection of T cells in vitro, and that HIV selectively infected and killed CD4+ but not CD8+ T-cell lines — direct experimental proof that CD4 itself, not merely "T cells" generically, was required for entry. Later transfection experiments showed that non-human cells engineered to express human CD4 became susceptible to HIV infection, confirming CD4 as necessary (though, as later found, insufficient without a coreceptor).

Discovery of coreceptors (1996) and the CCR5-Δ32 natural experiment. Edward Berger's group identified CXCR4 as a fusion cofactor, and several groups quickly identified CCR5 as the coreceptor for transmitted strains. The clinching natural experiment came from the observation that a subset of people repeatedly exposed to HIV through high-risk sex remained uninfected; these individuals were found to be homozygous for a 32-base-pair deletion in the CCR5 gene (CCR5-Δ32), producing a nonfunctional, non-surface-expressed receptor. Homozygotes (about 1% of people of European descent) are highly resistant to infection by R5 strains; heterozygotes progress to AIDS more slowly. This human genetic variant is the single most direct proof that CCR5 is essential in vivo, not merely in cell culture, and it later inspired the CCR5-targeting drug maraviroc and the "Berlin patient"/"London patient" cures via CCR5-Δ32/Δ32 stem cell transplants.

Quantifying viral dynamics — the Ho and Wei experiments (1995). David Ho and George Shaw's groups independently treated HIV-infected patients with potent antiretroviral drugs (protease inhibitors) and measured plasma viral RNA decline mathematically. Viral load fell in a biphasic exponential decay, with a half-life of about 1–2 days, from which they calculated that roughly 10 billion new virions are produced daily at steady state and that infected CD4 T cells themselves turn over with a half-life of about 1.5–2 days. This overturned the previously held view that HIV was mostly "latent" during clinical latency; instead, clinical latency is a dynamic steady state of massive ongoing viral replication and CD4 T-cell destruction and replacement, with the immune system barely keeping pace until it eventually fails. This quantitative result — grounded in real-time PCR measurement and differential equation modeling of decay curves — is considered one of the foundational proofs of HIV pathogenesis dynamics.

Establishing pyroptosis as the dominant killing mechanism (2013–2014). Gilad Doitsh, Warner Greene, and colleagues showed, using human lymphoid tissue explants ex vivo, that blocking caspase-1 (the pyroptosis executioner enzyme) with a chemical inhibitor prevented the death of the vast majority of CD4 T cells even though productive infection (measured by p24 antigen) was confined to a small minority of cells. This demonstrated experimentally that most CD4 T-cell death in lymphoid tissue is an inflammatory bystander phenomenon (abortive infection sensed by IFI16, triggering pyroptosis), not direct viral killing — refining the mechanistic picture established by the earlier dynamics studies.

Example 1 — a genetics cross for a primary immunodeficiency. X-linked agammaglobulinemia (XLA) is caused by loss-of-function mutations in BTK, located on the X chromosome, and is recessive. A phenotypically normal woman known to be a carrier (X^B X^b, where b is the mutant allele) has children with a man who is unaffected (X^B Y). Work out the expected offspring ratios and clinical outcomes. Gametes from the mother: ½ X^B, ½ X^b. Gametes from the father: ½ X^B, ½ Y.

Expected ratio among all offspring: 1 unaffected daughter : 1 carrier daughter : 1 unaffected son : 1 affected son — i.e., ¼ of all sons are affected, and ½ of daughters are carriers, with no daughters affected (recessive X-linked inheritance, matching the actual epidemiology of XLA, which occurs almost exclusively in males). An affected son will have profoundly low or absent serum immunoglobulins of all classes (B cells fail to mature past the pre-B stage because BTK signaling is required downstream of the pre-B-cell receptor) and will present in infancy with recurrent sinopulmonary infections from encapsulated bacteria, once maternal IgG (transferred transplacentally) wanes around 6 months of age. Note this is a purely humoral defect: T-cell numbers and cell-mediated immunity are normal, so this child handles most viral infections and live-virus vaccines fine but needs lifelong IVIG replacement.

Example 2 — a quantitative HIV progression scenario. A 32-year-old man is diagnosed with HIV. His baseline CD4 count is 520 cells/µL and his plasma viral load is 45,000 copies/mL. He declines therapy for personal reasons and is followed for 6 years, during which his CD4 count declines at a fairly typical untreated rate of roughly 50–80 cells/µL per year (a rate correlated with his relatively high baseline viral load — viral load is the strongest predictor of the rate of CD4 decline, a relationship established by Mellors and colleagues in the mid-1990s using large natural-history cohorts). Using the midpoint decline rate of 65 cells/µL/year: Projected CD4 at year 6 = 520 − (65 × 6) = 520 − 390 = 130 cells/µL. This value is below the 200 cells/µL AIDS threshold, so by year 6 this patient meets the immunological definition of AIDS even without yet having an opportunistic infection. At this CD4 range clinicians expect specific threshold-associated risks: oral/esophageal candidiasis and reactivation tuberculosis become common below ~350 cells/µL; Pneumocystis jirovecii pneumonia risk rises sharply below 200 cells/µL (the threshold at which prophylactic trimethoprim-sulfamethoxazole is started); disseminated Mycobacterium avium complex and CMV retinitis become major risks below 50 cells/µL. If he starts ART at year 6, immune reconstitution typically restores CD4 counts by roughly 100–150 cells/µL in the first year and continues rising over 2–4 years, though full normalization is less likely the lower the CD4 nadir was before treatment began — illustrating why early ART initiation (now the standard "treat immediately upon diagnosis" guideline) matters clinically, not just virologically.

Françoise Barré-Sinoussi trained as a virologist at the Institut Pasteur in Paris under Jean-Claude Chermann and Luc Montagnier, working initially on retroviruses in animal models before the AIDS epidemic redirected the lab's focus in 1983. When a Parisian dermatologist, Willy Rozenbaum, sent a lymph node biopsy from a patient with persistent lymphadenopathy — a syndrome then suspected to precede full-blown AIDS — Barré-Sinoussi's careful serial measurements of reverse transcriptase activity in cultured lymphocytes, day after day, over roughly two weeks, provided the first clean evidence of a new retrovirus replicating and killing the cultured cells. Her insistence on rigorous enzymatic and morphological (electron microscopy) confirmation, rather than resting on preliminary signals, was central to establishing LAV/HIV as a genuinely novel human retrovirus at a moment when several groups were racing to the same conclusion under intense public pressure.

Understanding primary immunodeficiencies now directly guides newborn screening: T-cell receptor excision circle (TREC) assays on dried blood spots detect SCID before infants develop fatal infections, allowing life-saving bone marrow transplantation in the first weeks of life. Gene therapy, using lentiviral vectors to correct the common gamma chain or ADA deficiency in autologous hematopoietic stem cells, has moved from experimental to approved therapy for several SCID variants. For HIV, the mechanistic understanding of CD4 depletion and viral dynamics directly shaped modern treatment: combination antiretroviral therapy (ART), targeting reverse transcriptase, protease, integrase, and (via maraviroc) the CCR5 coreceptor simultaneously, suppresses replication below the threshold where resistant mutants can be selected — a strategy derived directly from the mutation-rate and turnover numbers established by Ho, Wei, and colleagues. Pre-exposure prophylaxis (PrEP), using tenofovir/emtricitabine or long-acting injectable cabotegravir, exploits the same drug targets to prevent establishment of infection in exposed but uninfected people. The discovery of CCR5 as an essential coreceptor led directly to the Berlin patient (Timothy Ray Brown) and subsequent cured patients, who received bone marrow transplants from CCR5-Δ32/Δ32 donors for unrelated leukemias and remain HIV-free off therapy — proof of concept for cure strategies now being pursued with gene-editing approaches (CRISPR-disrupted CCR5 in autologous stem cells). Public health programs built on U=U (undetectable = untransmittable) messaging, informed directly by viral dynamics data, have reshaped HIV prevention counseling worldwide. The same conceptual framework — mapping specific immune cell losses onto specific infection risks — underlies modern management of iatrogenic immunosuppression in transplant recipients and cancer patients, and it foreshadows the broader study of Host-Pathogen Interactions, where pathogens are understood not just by what they do, but by which specific host defense they have learned to exploit.

Ask the tutor: How exactly does the latent HIV reservoir evade immune detection, and what strategies (shock-and-kill, gene editing) are being tested to eliminate it?